Radiopharm Theranostics LTD

Lantheus Holdings, through its subsidiaries, has disclosed a significant beneficial ownership of 20.9% in Radiopharm Theranostics Limited, detailing strategic investments and co-development partnerships.

Lantheus Omega, LLC, along with its parent entities, has reported beneficial ownership of 17.3% of Radiopharm Theranostics Limited's ordinary shares, including significant option holdings.

JPMorgan Chase & Co. has filed an amendment to its Schedule 13G, reporting a 4.0% beneficial ownership stake in Radiopharm Theranostics Limited as of December 31, 2025.

Regal Partners entities have reported a significant 9.05% beneficial ownership stake in Radiopharm Theranostics Limited, comprising over 320 million shares.

Regal Funds Management Pty Limited and Regal Partners Limited have disclosed a beneficial ownership of 7.30% in Radiopharm Theranostics Limited, totaling 172,634,988 shares.

JPMorgan Chase & Co. has filed an amended Schedule 13G, revealing a beneficial ownership of 9.0% in Radiopharm Theranostics Limited's American Depositary Shares.

Regal Funds Management Pty Limited and Regal Partners Limited have disclosed a beneficial ownership of 9.03% in Radiopharm Theranostics Limited, totaling over 210 million shares.